Abstract | OBJECTIVES: METHODS: Peritoneal metastasis is a common sign of advanced tumor stage, tumor progression or disease recurrence in patients with GC. Recently, the role of HER2 overexpression in GC, occurring in about 20% of cases, is correlated with a worse prognosis. We report the case of 61-years old female, admitted to our Hospital after curative surgery for GC with over-expression of HER2. Seven months after the start of first line chemotherapy treatment a pleuro- peritoneal disease progression occurred, documented by cytological exam; according to HER2 status, we decided to treat the patient with IP trastuzumab administration. RESULTS: Between September and October 2012, the patient (ECOG performance status was 0), underwent to 6 cycles of IP trastuzumab. Trastuzumab was administered weekly at a dose of 150 mg for each cycle after paracentesis. The safety was good, no local complications (e.g. abdominal pain, peritonitis) occurred. The clinical revaluation evidenced a stable peritoneal disease. CONCLUSIONS: To our knowledge this is the first report on Trastuzumab use to treat IP metastases from GC, with acceptable toxicity and local disease control.
|
Authors | M Berretta, R Fisichella, E Borsatti, A Lleshi, S Ioffredo, N Meneguzzo, V Canzonieri, A Di Grazia, R Cannizzaro, U Tirelli, S Berretta |
Journal | European review for medical and pharmacological sciences
(Eur Rev Med Pharmacol Sci)
Vol. 18
Issue 5
Pg. 689-92
( 2014)
ISSN: 2284-0729 [Electronic] Italy |
PMID | 24668709
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Trastuzumab
|
Topics |
- Antineoplastic Agents
(administration & dosage)
- Carcinoma
- Feasibility Studies
- Female
- Humans
- Injections, Intraperitoneal
- Middle Aged
- Neoplasm Recurrence, Local
(pathology)
- Peritoneal Neoplasms
(diagnosis, drug therapy, secondary)
- Stomach Neoplasms
(diagnosis, drug therapy)
- Trastuzumab
(administration & dosage)
- Treatment Outcome
|